Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05886764 · ClinicalTrials.gov registry record · NA

Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials

A NA study of Cancer and Malignant Neoplasm, sponsored by University of Chicago.

Recruiting
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT05886764 is a NA study of Cancer and Malignant Neoplasm that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 180 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05886764, a NA study of Cancer and Malignant Neoplasm, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interventions or no intervention (control arm).

Interventions

  • OTHER Digital Intervention
  • OTHER Community Outreach

Study Locations (1)

Illinois

  • University of Chicago Medicine Comprehensive Cancer Center - Chicago

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2023-10-23
Est. Completion 2027-07
Phase NA

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT05886764

The ClinicalTrials.gov registry entry for NCT05886764 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Digital Intervention is the first listed.

NCT05886764 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05886764 about?

NCT05886764 is a clinical study titled "Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials". This trial will study different outreach methods to assess impact on enrollment of underrepresented minorities (specifically African Americans) to early phase cancer clinical treatment trials. Both patients and providers (those seeing enrolled patients) will be enrolled and receive the study interve...

What is the current status of trial NCT05886764?

This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2023-10-23. Estimated completion is 2027-07.

What conditions does trial NCT05886764 study?

This clinical trial studies the following conditions: Cancer, Malignant Neoplasm, Malignancy.

What interventions are being tested in trial NCT05886764?

The interventions under investigation include: Digital Intervention (OTHER), Community Outreach (OTHER).

Who is sponsoring clinical trial NCT05886764?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05886764 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.